VAPE Holdings Inc. (OTC: VAPE), a provider of healthy, efficient, and sustainable products to lawfully operating participants in the legal cannabis industry, recently announced that it has filed its second patent application with the U.S. Patent & Trademark Office for a new class of cannabis-derived products for high-value bio-medical applications known as the “NG 200 Series Patents”.

“This patent application is for processes and methods of delivering specific cannabinoid formulations in treatment of a wide range of diseases and medical conditions,” said VAPE Holdings Inc. CSO Dr. Mark Scialdone in the press release. “Our expectation is that our innovations will be of particular interest to the medical community in the treatment of conditions in which successful therapeutic outcome is dependent on localized control of inflammation and pain.”

After filing for the patent, the company will focus on relatively low-cost pre-clinical testing to demonstrate efficacy and safety of preferred delivery methods, with the ultimate goal of commercializing the patents through licensing and partnerships with pharmaceutical and medical device companies developing products targeting diseases and conditions capable of being treated with cannabinoids.

The worldwide bio-medical materials market is worth in excess of $3 billion with attractive growth rates of between 10% and 15% annually. With a strong demand for medical devices and drug delivery formulations, the company’s technology addresses a sizable market that’s positioned to continue expanding.

Shares of Vape Holdings Inc. fell modestly in early trading on Tuesday, May 19, 2015 following the news release.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: